董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| 汉雨生 | 男 | chairman of the board and chief executive officer | 46 | 未披露 | 2101.20 | 2025-04-29 |
| Wendy Hayes | 女 | Independent director | 55 | 未披露 | 未持股 | 2025-04-29 |
| Gang Lu | 男 | Director | 53 | 未披露 | 未持股 | 2025-04-29 |
| 张之宏 | 男 | Director and Chief Technology Officer | 49 | 未披露 | 112.50 | 2025-04-29 |
| Licen Lisa Xu | 女 | Independent director | 59 | 未披露 | 未持股 | 2025-04-29 |
| Feng Deng | 男 | Director | 61 | 未披露 | 1188.02 | 2025-04-29 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| 汉雨生 | 男 | chairman of the board and chief executive officer | 46 | 未披露 | 2101.20 | 2025-04-29 |
| 张之宏 | 男 | Director and Chief Technology Officer | 49 | 未披露 | 112.50 | 2025-04-29 |
| Xiaozhi Hu | 女 | Senior director in finance | 41 | 未披露 | 未持股 | 2025-04-29 |
董事简历
中英对照 | 中文 | 英文- 汉雨生
-
汉雨生，是Burning Rock Biotech Limited创始人、董事长兼首席执行官。Han 先生拥有17年的生命科学经验。从2011年6月到2013年11月，他是Northern Light Venture Capital的合伙人，专注于医疗保健行业的投资，并帮助公司投资成功的公司。从2005年7月到2009年5月，他在BioTek Instruments, Inc.工作，担任中国区总经理。在BioTek Instruments China任职期间，他建立并领导了营销、销售和售后团队。从2003年9月到2005年5月，他担任Gene Company Limited的产品专家。他于2000年7月获得吉林大学生物化学学士学位，2003年6月获得北京协和医学院细胞生物学硕士学位。他于2011年5月获得哥伦比亚商学院工商管理硕士学位。
Yusheng Han,is Burning Rock Biotech Limited founder, chairman of the board of directors and chief executive officer. From June 2011 to November 2013, he was an associate in Northern Light Venture Capital where he focused on investment in the healthcare industry and helped the firm invest in successful companies. From July 2005 to May 2009, Mr. Han worked at BioTek Instruments, Inc. as its general manager in China. During his term with BioTek Instruments China, he built and led teams across marketing, sales and post-sale. From September 2003 to May 2005, he served as the product specialist of Gene Company Limited. Mr. Han received a bachelor's degree in biochemistry from Jilin University in July 2000, and a master's degree in cell biology in Peking Union Medical College in June 2003. He obtained a Master of Business Administration degree from Columbia Business School in May 2011. - 汉雨生，是Burning Rock Biotech Limited创始人、董事长兼首席执行官。Han 先生拥有17年的生命科学经验。从2011年6月到2013年11月，他是Northern Light Venture Capital的合伙人，专注于医疗保健行业的投资，并帮助公司投资成功的公司。从2005年7月到2009年5月，他在BioTek Instruments, Inc.工作，担任中国区总经理。在BioTek Instruments China任职期间，他建立并领导了营销、销售和售后团队。从2003年9月到2005年5月，他担任Gene Company Limited的产品专家。他于2000年7月获得吉林大学生物化学学士学位，2003年6月获得北京协和医学院细胞生物学硕士学位。他于2011年5月获得哥伦比亚商学院工商管理硕士学位。
- Yusheng Han,is Burning Rock Biotech Limited founder, chairman of the board of directors and chief executive officer. From June 2011 to November 2013, he was an associate in Northern Light Venture Capital where he focused on investment in the healthcare industry and helped the firm invest in successful companies. From July 2005 to May 2009, Mr. Han worked at BioTek Instruments, Inc. as its general manager in China. During his term with BioTek Instruments China, he built and led teams across marketing, sales and post-sale. From September 2003 to May 2005, he served as the product specialist of Gene Company Limited. Mr. Han received a bachelor's degree in biochemistry from Jilin University in July 2000, and a master's degree in cell biology in Peking Union Medical College in June 2003. He obtained a Master of Business Administration degree from Columbia Business School in May 2011.
- Wendy Hayes
-
Wendy Hayes ，自2020年6月起担任Burning Rock Biotech Limited独立董事。她曾担任Tuanche Limited （NASDAQ： TC）的独立董事（2018年11月以来）、iHuman Inc. （NYSE： IH）、Gracell Biotechnologies Inc. （NASDAQ： GRCL）（2021年1月以来）、SciClone Pharmaceuticals （Holdings） Limited （HKEX： 6600）（2021年3月以来）。2013年5月至2018年9月，她曾担任the Public Company Accounting Oversight Board在美国的检查主管。在此之前，她曾担任Deloitte （中国）的审计合伙人。她于1991年获得对外经济贸易大学国际金融学士学位，并于2012年获得张Kong Graduate School of Business的emba学位。她目前是哈佛大学ALI的高级研究员。她是美国（加州）和中国的注册会计师。
Wendy Hayes,has served as independent director since June 2020. Ms. Hayes has served as an independent director of iHuman Inc. (NYSE: IH) since October 2020, and Apollomics Inc. (NASDAQ: APLM) since March 2023. Ms. Hayes served as the inspections leader at the Public Company Accounting Oversight Board in the United States. Prior to that, Ms. Hayes was an audit partner at Deloitte (China). Ms. Hayes received her bachelor's degree in international finance from University of International Business and Economics in 1991, and her executive MBA from Cheung Kong Graduate School of Business in 2012. Ms. Hayes is a certified public accountant in the United States (California) and China. - Wendy Hayes ，自2020年6月起担任Burning Rock Biotech Limited独立董事。她曾担任Tuanche Limited （NASDAQ： TC）的独立董事（2018年11月以来）、iHuman Inc. （NYSE： IH）、Gracell Biotechnologies Inc. （NASDAQ： GRCL）（2021年1月以来）、SciClone Pharmaceuticals （Holdings） Limited （HKEX： 6600）（2021年3月以来）。2013年5月至2018年9月，她曾担任the Public Company Accounting Oversight Board在美国的检查主管。在此之前，她曾担任Deloitte （中国）的审计合伙人。她于1991年获得对外经济贸易大学国际金融学士学位，并于2012年获得张Kong Graduate School of Business的emba学位。她目前是哈佛大学ALI的高级研究员。她是美国（加州）和中国的注册会计师。
- Wendy Hayes,has served as independent director since June 2020. Ms. Hayes has served as an independent director of iHuman Inc. (NYSE: IH) since October 2020, and Apollomics Inc. (NASDAQ: APLM) since March 2023. Ms. Hayes served as the inspections leader at the Public Company Accounting Oversight Board in the United States. Prior to that, Ms. Hayes was an audit partner at Deloitte (China). Ms. Hayes received her bachelor's degree in international finance from University of International Business and Economics in 1991, and her executive MBA from Cheung Kong Graduate School of Business in 2012. Ms. Hayes is a certified public accountant in the United States (California) and China.
- Gang Lu
-
Gang Lu ， 2014年6月起担任Burning Rock Biotech Limited董事。2009年，他加入了Lenovo star （一家总部位于北京的风险投资公司），他现在是Lenovo star 的合伙人，领导医疗保健投资，专注于创新医药、生物和基因技术以及创新医疗服务领域。他持有西安电子科技大学的电磁工程学士学位和清华大学的工商管理硕士学位。
Gang Lu,has served as director since June 2014. In 2009, Mr. Lu joined Legend Star, a venture capital headquartered in Beijing, and he is now a partner of Legend Star and leads investment in healthcare, specialized in the fields of innovative medicine, biological and genetic technology, and innovative medical service. Mr. Lu holds a bachelor's degree in electromagnetic engineering from Xidian University and a Master of Business Administration degree from Tsinghua University. - Gang Lu ， 2014年6月起担任Burning Rock Biotech Limited董事。2009年，他加入了Lenovo star （一家总部位于北京的风险投资公司），他现在是Lenovo star 的合伙人，领导医疗保健投资，专注于创新医药、生物和基因技术以及创新医疗服务领域。他持有西安电子科技大学的电磁工程学士学位和清华大学的工商管理硕士学位。
- Gang Lu,has served as director since June 2014. In 2009, Mr. Lu joined Legend Star, a venture capital headquartered in Beijing, and he is now a partner of Legend Star and leads investment in healthcare, specialized in the fields of innovative medicine, biological and genetic technology, and innovative medical service. Mr. Lu holds a bachelor's degree in electromagnetic engineering from Xidian University and a Master of Business Administration degree from Tsinghua University.
- 张之宏
-
张之宏 自2016年3月起担任Burning Rock Biotech Limited首席技术官。在加入Burning Rock Biotech Limited之前，他是Illumina, Inc.的员工科学家，以及Howard Hughes Medical Institute和University of Washington的高级研究员。1997年和2000年分别获得复旦大学生物化学和分子生物学学士和硕士学位，2005年获得杜克大学分子遗传学和微生物学博士学位。
Zhihong Zhang,has served as chief technology officer in March 2016 and director since June 2023. Prior to joining , Dr. Zhang was a staff scientist of Illumina, Inc., and a senior fellow of Howard Hughes Medical Institute and University of Washington. He obtained a bachelor's and master's degree in biochemistry and molecular biology from Fudan University in 1997 and 2000, and a Ph.D. degree in molecular genetics and microbiology from Duke University in 2005. - 张之宏 自2016年3月起担任Burning Rock Biotech Limited首席技术官。在加入Burning Rock Biotech Limited之前，他是Illumina, Inc.的员工科学家，以及Howard Hughes Medical Institute和University of Washington的高级研究员。1997年和2000年分别获得复旦大学生物化学和分子生物学学士和硕士学位，2005年获得杜克大学分子遗传学和微生物学博士学位。
- Zhihong Zhang,has served as chief technology officer in March 2016 and director since June 2023. Prior to joining , Dr. Zhang was a staff scientist of Illumina, Inc., and a senior fellow of Howard Hughes Medical Institute and University of Washington. He obtained a bachelor's and master's degree in biochemistry and molecular biology from Fudan University in 1997 and 2000, and a Ph.D. degree in molecular genetics and microbiology from Duke University in 2005.
- Licen Lisa Xu
-
Licen Lisa Xu是FlashDx Inc.（一家分子诊断即时护理解决方案公司）的首席商务官，以及Ribbon Biolab（一家专门生产合成dna的公司）的独立董事会成员。她曾担任罗氏诊断公司（Roche Holding AG的子公司，负责诊断测试、仪器和数字解决方案的开发）的战略产品管理和生命周期管理副总裁，以及Illumina公司的战略营销和产品管理副总裁。她拥有苏黎世大学（University of Zurich）的分子生物学博士学位和清华大学（Tsinghua University）的生物物理学硕士学位，并完成了宾夕法尼亚大学（University of Pennsylvania）沃顿商学院（Wharton business School）的企业高管教育项目。
Licen Lisa Xu,has served as independent director since June 2022. Dr. Xu has 17 years of experience in driving the productization and lifecycle for life science and biomedical products, from product concept and research to development and commercialization. She is the chief commercial officer of FlashDx Inc., a molecular diagnostics sample-to-answer solution company, and an independent board member of Ribbon Biolab, a company specialized in the production of synthetic DNAs. Dr. Xu served as a vice president on strategic product management and lifecycle management at Roche Diagnostics, a subsidiary of Roche Holding AG for the development of diagnostic tests, instruments and digital solutions, and a vice president on strategic marketing and product management at Illumina Inc. Dr. Xu has a Ph.D. degree in molecular biology from University of Zurich and a master of science degree in biophysics from Tsinghua University, and completed the business executive education program from Wharton Business School, University of Pennsylvania. - Licen Lisa Xu是FlashDx Inc.（一家分子诊断即时护理解决方案公司）的首席商务官，以及Ribbon Biolab（一家专门生产合成dna的公司）的独立董事会成员。她曾担任罗氏诊断公司（Roche Holding AG的子公司，负责诊断测试、仪器和数字解决方案的开发）的战略产品管理和生命周期管理副总裁，以及Illumina公司的战略营销和产品管理副总裁。她拥有苏黎世大学（University of Zurich）的分子生物学博士学位和清华大学（Tsinghua University）的生物物理学硕士学位，并完成了宾夕法尼亚大学（University of Pennsylvania）沃顿商学院（Wharton business School）的企业高管教育项目。
- Licen Lisa Xu,has served as independent director since June 2022. Dr. Xu has 17 years of experience in driving the productization and lifecycle for life science and biomedical products, from product concept and research to development and commercialization. She is the chief commercial officer of FlashDx Inc., a molecular diagnostics sample-to-answer solution company, and an independent board member of Ribbon Biolab, a company specialized in the production of synthetic DNAs. Dr. Xu served as a vice president on strategic product management and lifecycle management at Roche Diagnostics, a subsidiary of Roche Holding AG for the development of diagnostic tests, instruments and digital solutions, and a vice president on strategic marketing and product management at Illumina Inc. Dr. Xu has a Ph.D. degree in molecular biology from University of Zurich and a master of science degree in biophysics from Tsinghua University, and completed the business executive education program from Wharton Business School, University of Pennsylvania.
- Feng Deng
-
Feng Deng， 自2006年7月起担任公司董事。自2005年12月起担任Northern Light Venture Capital（一家由他联合创立的风险投资公司）管理董事。他持有清华大学电子工程理学学士和硕士学位；南加利佛尼亚大学计算机工程硕士学位和宾夕法尼亚大学沃顿商学院工商管理硕士学位。
Feng Deng,has served as director since August 2016. He founded Northern Light Venture Capital in January 2006 and served as its founding managing partner, focusing on investment in technology, media and telecom, or TMT, clean technology, healthcare and consumer sectors. From February 2004 to February 2005, he served as the vice president in strategy in Juniper Networks. From October 1997 to February 2004, Mr. Deng served as the vice president in engineering, chief strategy officer and a director of NetScreen Technologies Inc. Prior to NetScreen, he worked at Intel Corporation as a systems architect from July 1993 to October 1997. He holds a bachelor's and a master's degree in electronic engineering from Tsinghua University, a master's degree in computer engineering from the University of Southern California, and a Master of Business Administration degree from the Wharton Business School of the University of Pennsylvania. - Feng Deng， 自2006年7月起担任公司董事。自2005年12月起担任Northern Light Venture Capital（一家由他联合创立的风险投资公司）管理董事。他持有清华大学电子工程理学学士和硕士学位；南加利佛尼亚大学计算机工程硕士学位和宾夕法尼亚大学沃顿商学院工商管理硕士学位。
- Feng Deng,has served as director since August 2016. He founded Northern Light Venture Capital in January 2006 and served as its founding managing partner, focusing on investment in technology, media and telecom, or TMT, clean technology, healthcare and consumer sectors. From February 2004 to February 2005, he served as the vice president in strategy in Juniper Networks. From October 1997 to February 2004, Mr. Deng served as the vice president in engineering, chief strategy officer and a director of NetScreen Technologies Inc. Prior to NetScreen, he worked at Intel Corporation as a systems architect from July 1993 to October 1997. He holds a bachelor's and a master's degree in electronic engineering from Tsinghua University, a master's degree in computer engineering from the University of Southern California, and a Master of Business Administration degree from the Wharton Business School of the University of Pennsylvania.
高管简历
中英对照 | 中文 | 英文- 汉雨生
汉雨生，是Burning Rock Biotech Limited创始人、董事长兼首席执行官。Han 先生拥有17年的生命科学经验。从2011年6月到2013年11月，他是Northern Light Venture Capital的合伙人，专注于医疗保健行业的投资，并帮助公司投资成功的公司。从2005年7月到2009年5月，他在BioTek Instruments, Inc.工作，担任中国区总经理。在BioTek Instruments China任职期间，他建立并领导了营销、销售和售后团队。从2003年9月到2005年5月，他担任Gene Company Limited的产品专家。他于2000年7月获得吉林大学生物化学学士学位，2003年6月获得北京协和医学院细胞生物学硕士学位。他于2011年5月获得哥伦比亚商学院工商管理硕士学位。
Yusheng Han,is Burning Rock Biotech Limited founder, chairman of the board of directors and chief executive officer. From June 2011 to November 2013, he was an associate in Northern Light Venture Capital where he focused on investment in the healthcare industry and helped the firm invest in successful companies. From July 2005 to May 2009, Mr. Han worked at BioTek Instruments, Inc. as its general manager in China. During his term with BioTek Instruments China, he built and led teams across marketing, sales and post-sale. From September 2003 to May 2005, he served as the product specialist of Gene Company Limited. Mr. Han received a bachelor's degree in biochemistry from Jilin University in July 2000, and a master's degree in cell biology in Peking Union Medical College in June 2003. He obtained a Master of Business Administration degree from Columbia Business School in May 2011.- 汉雨生，是Burning Rock Biotech Limited创始人、董事长兼首席执行官。Han 先生拥有17年的生命科学经验。从2011年6月到2013年11月，他是Northern Light Venture Capital的合伙人，专注于医疗保健行业的投资，并帮助公司投资成功的公司。从2005年7月到2009年5月，他在BioTek Instruments, Inc.工作，担任中国区总经理。在BioTek Instruments China任职期间，他建立并领导了营销、销售和售后团队。从2003年9月到2005年5月，他担任Gene Company Limited的产品专家。他于2000年7月获得吉林大学生物化学学士学位，2003年6月获得北京协和医学院细胞生物学硕士学位。他于2011年5月获得哥伦比亚商学院工商管理硕士学位。
- Yusheng Han,is Burning Rock Biotech Limited founder, chairman of the board of directors and chief executive officer. From June 2011 to November 2013, he was an associate in Northern Light Venture Capital where he focused on investment in the healthcare industry and helped the firm invest in successful companies. From July 2005 to May 2009, Mr. Han worked at BioTek Instruments, Inc. as its general manager in China. During his term with BioTek Instruments China, he built and led teams across marketing, sales and post-sale. From September 2003 to May 2005, he served as the product specialist of Gene Company Limited. Mr. Han received a bachelor's degree in biochemistry from Jilin University in July 2000, and a master's degree in cell biology in Peking Union Medical College in June 2003. He obtained a Master of Business Administration degree from Columbia Business School in May 2011.
- 张之宏
张之宏 自2016年3月起担任Burning Rock Biotech Limited首席技术官。在加入Burning Rock Biotech Limited之前，他是Illumina, Inc.的员工科学家，以及Howard Hughes Medical Institute和University of Washington的高级研究员。1997年和2000年分别获得复旦大学生物化学和分子生物学学士和硕士学位，2005年获得杜克大学分子遗传学和微生物学博士学位。
Zhihong Zhang,has served as chief technology officer in March 2016 and director since June 2023. Prior to joining , Dr. Zhang was a staff scientist of Illumina, Inc., and a senior fellow of Howard Hughes Medical Institute and University of Washington. He obtained a bachelor's and master's degree in biochemistry and molecular biology from Fudan University in 1997 and 2000, and a Ph.D. degree in molecular genetics and microbiology from Duke University in 2005.- 张之宏 自2016年3月起担任Burning Rock Biotech Limited首席技术官。在加入Burning Rock Biotech Limited之前，他是Illumina, Inc.的员工科学家，以及Howard Hughes Medical Institute和University of Washington的高级研究员。1997年和2000年分别获得复旦大学生物化学和分子生物学学士和硕士学位，2005年获得杜克大学分子遗传学和微生物学博士学位。
- Zhihong Zhang,has served as chief technology officer in March 2016 and director since June 2023. Prior to joining , Dr. Zhang was a staff scientist of Illumina, Inc., and a senior fellow of Howard Hughes Medical Institute and University of Washington. He obtained a bachelor's and master's degree in biochemistry and molecular biology from Fudan University in 1997 and 2000, and a Ph.D. degree in molecular genetics and microbiology from Duke University in 2005.
- Xiaozhi Hu
Xiaozhi Hu，2012年加入公司，现任财务高级董事。在此之前，她曾担任财务经理、高级财务经理和财务总监。在加入公司之前，她曾在中兴通讯公司和广东珠江投资有限公司工作。她于2006年获得上海财经大学的经济学和会计学士学位，并于2012年获得中山大学的会计硕士学位。
Xiaozhi Hu,has joined since 2012 and is current senior director in finance. Prior to that, she served as a finance manager, senior finance manager and director in finance, respectively. Before joining , she worked at ZTE Corporation and Guangdong Zhujiang Investment Co., Ltd. Ms. Hu obtained bachelor's degrees in economics and accounting from Shanghai University of Finance and Economics in 2006 and a master's degree in accounting from Sun Yat-sen University in 2012.- Xiaozhi Hu，2012年加入公司，现任财务高级董事。在此之前，她曾担任财务经理、高级财务经理和财务总监。在加入公司之前，她曾在中兴通讯公司和广东珠江投资有限公司工作。她于2006年获得上海财经大学的经济学和会计学士学位，并于2012年获得中山大学的会计硕士学位。
- Xiaozhi Hu,has joined since 2012 and is current senior director in finance. Prior to that, she served as a finance manager, senior finance manager and director in finance, respectively. Before joining , she worked at ZTE Corporation and Guangdong Zhujiang Investment Co., Ltd. Ms. Hu obtained bachelor's degrees in economics and accounting from Shanghai University of Finance and Economics in 2006 and a master's degree in accounting from Sun Yat-sen University in 2012.